Los Angeles, July 14, 2021 (GLOBE NEWSWIRE) -- Hidradenitis Suppurativa Pipeline Landscape: Novel Emerging Therapies and Key Pharmaceutical Companies Reinvigorates the Pipeline...
Biopharma stocks closed the holiday-shortened ...Full story available on Benzinga.com
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Buy | Buy | Strong Buy | Buy | Strong Sell |
| Technical Indicators | Sell | Strong Buy | Strong Buy | Neutral | Strong Sell |
| Summary | Neutral | Strong Buy | Strong Buy | Neutral | Strong Sell |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 2,725.40 | 2,765.00 | 2,706.70 | +87.4 | +3.31% | 3.64M | NASDAQ | |||
| 374.15 | 377.54 | 367.00 | +6.34 | +1.72% | 16.37M | NASDAQ | |||
| 195.27 | 196.40 | 189.76 | +9.20 | +4.94% | 27.77M | NYSE | |||
| 53.19 | 53.92 | 52.94 | +0.01 | +0.02% | 19.06M | NASDAQ | |||
| 120.76 | 121.07 | 119.33 | +0.95 | +0.79% | 1.93M | NYSE | |||
| 195.23 | 196.46 | 189.95 | +3.15 | +1.64% | 15.18M | NASDAQ | |||
| 4.44 | 4.47 | 4.44 | 0.000 | 0.00% | 0.00 | NYSE | |||
| 43.50 | 43.74 | 42.26 | +1.40 | +3.33% | 38.31M | NYSE | |||
| 142.70 | 142.78 | 140.15 | +1.77 | +1.26% | 4.42M | NASDAQ | |||
| 21.17 | 21.25 | 20.91 | +0.18 | +0.86% | 7.68M | NYSE | |||
| 53.84 | 53.92 | 53.02 | +0.24 | +0.45% | 101.04K | NYSE | |||
| 41.47 | 41.87 | 39.80 | +2.11 | +5.36% | 51.31M | NYSE | |||
| 198.58 | 200.19 | 198.10 | -1.89 | -0.94% | 1.06M | NYSE | |||
| 61.27 | 61.55 | 60.43 | +0.11 | +0.18% | 715.88K | NYSE | |||
| 13.16 | 13.25 | 12.91 | +0.21 | +1.62% | 1.84M | NYSE |
ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.
